# Kenvue

> Kenvue is the world's largest pure-play consumer health company by revenue, spun out of Johnson & Johnson in 2023. It owns a portfolio of household brands - Tylenol, Neutrogena, Listerine, Band-Aid, Aveeno, Johnson's, Zyrtec and Nicorette among them - organized across Self Care, Skin Health & Beauty, and Essential Health. With roughly $15 billion in annual sales and products sold in more than 165 countries, Kenvue sits at the intersection of healthcare and everyday consumer goods. In November 2025 it agreed to be acquired by Kimberly-Clark in a cash-and-stock deal valued near $48.7 billion.

- **Founded:** 2022
- **Headquarters:** Summit, New Jersey, United States
- **Founders:** Johnson & Johnson (Parent company (spun off Kenvue in 2023))
- **Team size:** ~22,000 employees ('Kenvuers')
- **Products:** Self Care, Skin Health & Beauty, Essential Health, Tylenol, Neutrogena
- **Notable:** Became the world's largest pure-play consumer health company by revenue upon its 2023 spin-off from Johnson & Johnson., Completed the largest US IPO of 2023, raising roughly $4.37 billion - more than every other US IPO that year combined., Debuted with a market value of about $41 billion.

## Products & services

- **Self Care** — OTC medicines and wellness products including Tylenol, Motrin, Zyrtec, Benadryl, Sudafed, Nicorette, Nicoderm CQ, Imodium, Pepcid and Zarbee's.
- **Skin Health & Beauty** — Skin care and beauty brands including Neutrogena, Aveeno, Clean & Clear and OGX.
- **Essential Health** — Everyday care staples including Band-Aid, Listerine, Johnson's, Desitin, Bengay and o.b.
- **Tylenol** — Acetaminophen-based pain and fever relief, Kenvue's flagship analgesic brand.
- **Neutrogena** — Dermatologist-recommended skincare and suncare line, one of Kenvue's largest brands.
- **Listerine** — Antiseptic mouthwash and oral care range.

## Achievements

- Became the world's largest pure-play consumer health company by revenue upon its 2023 spin-off from Johnson & Johnson.
- Completed the largest US IPO of 2023, raising roughly $4.37 billion - more than every other US IPO that year combined.
- Debuted with a market value of about $41 billion.
- Owns a portfolio of iconic brands including Tylenol, Neutrogena, Listerine, Band-Aid, Aveeno, Johnson's, Zyrtec and Nicorette.
- Reached products sold in more than 165 countries with around $15 billion in annual sales.

## Latest updates

- **2026-01** — Kenvue shareholders overwhelmingly approved the ~$48.7 billion acquisition by Kimberly-Clark; closing targeted for the second half of 2026.
- **2025-11** — Kimberly-Clark agreed to acquire Kenvue in a cash-and-stock deal valued at about $48.7 billion, creating a combined company with roughly $32 billion in revenue.
- **2025-10** — Texas Attorney General sued Kenvue and Johnson & Johnson over Tylenol marketing, following unproven federal claims linking acetaminophen to autism.
- **2025-09** — The Trump administration publicly linked Tylenol/acetaminophen use in pregnancy to autism - an unproven claim - pressuring Kenvue's stock and reviving litigation.
- **2025-07** — Kenvue removed CEO Thibaut Mongon and named board member Kirk Perry interim CEO amid a strategic review and activist-investor pressure.

## Links

- Website: https://kenvue.com
- LinkedIn: http://www.linkedin.com/company/kenvue
- Twitter/X: https://twitter.com/kenvue
- YouTube: https://www.youtube.com/@kenvue
- Instagram: https://www.instagram.com/kenvue
- Facebook: https://facebook.com/Kenvue

---

Profile page: https://yespress.io/kenvue
Published by YesPress — https://yespress.io
Last updated: 2026-08-12